Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$0.51
$0.01(2.07%)
At close: 4:00 PM EDT
$0.51
$0.01(2.07%)
Day’s Range― - ―
52-Week Range$0.47 - $4.00
Previous CloseN/A
Volume40.38K
Average Volume (3M)936.14K
Market Cap
$27.80M
Enterprise Value$30.86
Total Cash (Recent Filing)$8.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Nov 05, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding56,349,170
10 Day Avg. Volume1,789,720
30 Day Avg. Volume936,141
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside586.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$448.75K
Bulls Say, Bears Say
Bulls Say
Proprietary ECG Platform And IPThe patented TriCor platform and multiple device formats create a defensible technology base. Broad IP coverage and flexibility across post-discharge, ambulatory and remote monitoring use cases could support licensing and adoption over several years.
Clinical And Regulatory ProgressRapid enrollment and advancing FDA engagement strengthen clinical credibility and clarify the path toward a pivotal heart-attack detection study. Positive validation could expand HeartBeam beyond arrhythmia monitoring and improve strategic partnering prospects.
Debt-Free Balance Sheet And Cost EfficiencyZero debt limits refinancing pressure while lower operating cash use and tighter spending extend financial flexibility. These improvements do not eliminate funding needs, but they provide more time to complete trials and develop commercial revenue.
Bears Say
No Revenue And Deepening LossesA lack of reported revenue means the business has not yet demonstrated commercial demand or a self-funding model. Widening losses despite substantial operating investment reduce visibility into sustainable margins and profitability.
Persistent Cash Burn And Financing DependenceHeavy cash consumption requires continued cost control and external capital before commercialization becomes self-sustaining. The new equity facility improves funding access but can increase dilution and reflects the company’s dependence on financing.
Regulatory And Adoption Execution RiskThe heart-attack indication remains unapproved, and FDA feedback could require additional evidence, delaying commercialization. Even with clearance, scaling depends on embedding the device into practice workflows, creating execution risk beyond product development.
HeartBeam News
BEAT FAQ
What was Heartbeam, Inc.’s price range in the past 12 months?
Heartbeam, Inc. lowest stock price was $0.47 and its highest was $4.00 in the past 12 months.
What is Heartbeam, Inc.’s market cap?
Heartbeam, Inc.’s market cap is $27.80M.
When is Heartbeam, Inc.’s upcoming earnings report date?
Heartbeam, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Heartbeam, Inc.’s earnings last quarter?
Heartbeam, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.086 by -$0.014.
Is Heartbeam, Inc. overvalued?
According to Wall Street analysts Heartbeam, Inc.’s price is currently Undervalued.
Does Heartbeam, Inc. pay dividends?
Heartbeam, Inc. does not currently pay dividends.
What is Heartbeam, Inc.’s EPS estimate?
Heartbeam, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Heartbeam, Inc. have?
Heartbeam, Inc. has 56,349,170 shares outstanding.
What happened to Heartbeam, Inc.’s price movement after its last earnings report?
Heartbeam, Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.086. Following the earnings report the stock price went down -15.28%.
Which hedge fund is a major shareholder of Heartbeam, Inc.?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartbeam, Inc.
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
BEAT Company Deck
BEAT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress on clinical validation, strong IP protection, completed product development milestones, early commercial deployments, and improving cash efficiency — all meaningful positives. Key risks remain: commercial revenue is nascent, regulatory approval for the heart attack detection indication is pending (pre-submitted to FDA), cash balances require disciplined execution to reach profitability, and a leadership transition created near-term one-time costs. On balance, the highlights (clinical momentum, regulatory progress, IP strength, cost reductions and runway extension) outweigh the lowlights (early revenue, regulatory uncertainty, continued net losses), supporting a cautiously positive outlook.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$3.50
▲(586.27% Upside)
Technical Analysis
Ownership Overview
16.84% Insiders
2.57% Mutual Funds
4.67% Other Institutional Investors
71.90% Public Companies and
Individual Investors